XCUR - Exicure Inc

XCUR - Exicure Inc

https://www.exicuretx.com

Momentum: Bearish

Recent News

Powered by Alpha Vantage

Exicure Posts Wider Loss in Fiscal Q2

Motley Fool • 1 month ago • score: 0.13

Exicure ( NASDAQ:XCUR ) , a biotechnology company that recently pivoted its business model following the acquisition of GPCR Therapeutics USA Inc, reported its second quarter 2025 earnings on August 8, 2025. The main headlines from this release included another quarter of no reported revenue and ...

Exicure Stock Is Soaring After The Bell: What's Driving The Action? - Exicure ( NASDAQ:XCUR )

Benzinga • 11 months, 3 weeks ago • score: 0.37

Shares of low-float micro-cap stock Exicure Inc XCUR are rocketing higher in Wednesday's after-hours session after the company announced that it received an extension from the Nasdaq Hearings Panel. What Happened: After the market close, Exicure announced that it was granted an extension for ...

Reneo Pharmaceuticals And 2 Other Stocks Under $5 Executives Are Buying - Exicure ( NASDAQ:XCUR )

Benzinga • 11 months, 4 weeks ago • score: 0.29

The Dow Jones index closed higher by over 200 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading ...

What's Going On With Exicure Shares Monday? - Exicure ( NASDAQ:XCUR )

Benzinga • 11 months, 4 weeks ago • score: 0.68

Exicure, Inc. XCUR stock is trading higher on Monday after the company entered into debt-for-equity exchange agreements. What Happened: On Friday, Exicure filed a Form 8-K with the Securities and Exchange Commission that signaled that it entered into debt-for-equity agreements with DGP and ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Exicure, Inc., a clinical-stage biotechnology company, develops therapies for neurology, immuno-oncology, inflammatory diseases, and genetic disorders based on its proprietary spherical nucleic acid (SNA) technology. The company is headquartered in Chicago, Illinois.

52W High

$36.00

52W Low

$1.44

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

3.85

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-0.04

EV/Revenue (<3 favorable)

27.17

P/S (TTM) (<3 favorable)

74.42

P/B (<3 favorable)

3.39

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

63.15%

Institutions (25–75% balanced)

12.88%

Shares Outstanding

6,317,800

Float

2,327,900

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

0

Gross Profit (TTM)

-1,743,000

EPS (TTM)

-3.86

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-1.51%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

9.28

Momentum

Bearish momentum

Value

-0.9945

Previous

-0.9900

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025